Avadel Pharmaceuticals (AVDL) Amortization of Deferred Charges (2018 - 2022)
Historic Amortization of Deferred Charges for Avadel Pharmaceuticals (AVDL) over the last 5 years, with Q4 2022 value amounting to $1.9 million.
- Avadel Pharmaceuticals' Amortization of Deferred Charges rose 51254.02% to $1.9 million in Q4 2022 from the same period last year, while for Dec 2022 it was $6.1 million, marking a year-over-year increase of 38493.59%. This contributed to the annual value of $2.8 million for FY2023, which is 5380.04% down from last year.
- Per Avadel Pharmaceuticals' latest filing, its Amortization of Deferred Charges stood at $1.9 million for Q4 2022, which was up 51254.02% from $1.9 million recorded in Q3 2022.
- Avadel Pharmaceuticals' 5-year Amortization of Deferred Charges high stood at $1.9 million for Q3 2022, and its period low was $311000.0 during Q4 2021.
- Its 5-year average for Amortization of Deferred Charges is $1.2 million, with a median of $1.5 million in 2019.
- Per our database at Business Quant, Avadel Pharmaceuticals' Amortization of Deferred Charges plummeted by 8158.67% in 2021 and then surged by 51474.36% in 2022.
- Over the past 5 years, Avadel Pharmaceuticals' Amortization of Deferred Charges (Quarter) stood at $1.4 million in 2018, then increased by 10.01% to $1.6 million in 2019, then rose by 7.51% to $1.7 million in 2020, then plummeted by 81.59% to $311000.0 in 2021, then soared by 512.54% to $1.9 million in 2022.
- Its last three reported values are $1.9 million in Q4 2022, $1.9 million for Q3 2022, and $1.9 million during Q2 2022.